DOW JONES27,960.80-1031.61 -3.56%
S&P 5003,225.89-111.86 -3.35%
NASDAQ9,221.28-355.31 -3.71%

Chi-Med Highlights Updated Phase II Savolitinib / Imfinzi Combination Data in Advanced Papillary Renal Cell Carcinoma at 2020 ASCO Genitourinary Cancers Symposium

Hutchison China MediTech Limited (Nasdaq: HCM) today announced the availability of updated results from the Phase II CALYPSO study of the savolitinib / Imfinzi® (durvalumab) combination in a cohort of patients with metastatic papillary renal cell carcinoma ("P

Benzinga · 02/10/2020 09:33

Hutchison China MediTech Limited (Nasdaq: HCM) today announced the availability of updated results from the Phase II CALYPSO study of the savolitinib / Imfinzi® (durvalumab) combination in a cohort of patients with metastatic papillary renal cell carcinoma ("PRCC"), an investigator initiated study led by Professor Thomas Powles, Lead for Solid Tumour Research at Barts Cancer Institute, and sponsored by Queen Mary University of London.
 
Full data from the PRCC cohort of the CALYPSO study will be presented on Saturday, February 15, 2020, in oral and poster presentations at the annual American Society of Clinical Oncology Genitourinary Cancers Symposium ("ASCO GU") in San Francisco, CA.
 
Further details from the presentation are as follows:
 
Presentation Title:
Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer
Presenting Author:
Cristina Suarez Rodriguez, MD, Hospital Univ. Vall D Hebron General, Barcelona, Spain
Other Authors:
Thomas Powles, James M. G. Larkin, Poulam Patel, Begoña Pérez-Valderrama, Alejo Rodriguez-Vida, Hilary Glen, Fiona Thistlethwaite, Christy Ralph, Srinivasan Gopalakrishnan, Maria Jose Mendez-Vidal, Kelly Mousa, Aaron Prendergast, Laura Vosper, Wing-Kin Liu
Abstract #:
619 / Board D5
Oral Presentation:
Rapid Abstract Session C: Renal Cell Cancer
Date & Time:
Saturday, February 15: 10:00 AM-11:30 AM PST
Poster Presentation:
Session C: Renal Cell Cancer
Date & Time:
Saturday, February 16: 7:00 AM-7:55 AM and 12:30 AM-2:00 PM PST
 
Preliminary results of this study (cut-off date of September 25, 2018) were first presented on February 16, 2019 at ASCO-GU.[1]